GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Signal Transduct Target Ther. 2020 Nov 17;5(1):267. doi: 10.1038/s41392-020-00391-5.

¹ Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, 42415, Republic of Korea.
² Department of Laboratory Medicine, College of Medicine, Yeungnam University, Yeungnam University Medical Center, Daegu, 42415, Republic of Korea.
³ Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea. [email protected].
⁴ Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul, 02792, Republic of Korea. [email protected].
⁵ Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea. [email protected].
⁶ Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. [email protected].

No abstract available

Publication types